LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed · Phase 3 · Has a placebo group

Conditions studied: Heavy Menstrual Bleeding, Uterine Fibroid

In brief

The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.

Key facts

Study ID
NCT03103087
Run by
Myovant Sciences GmbH
People needed
382
Starts
2017-06-14
Expected to finish
2020-09-16
Last updated by the study team
2022-04-20

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.